OSTEONECROSIS OF THE JAW ASSOCIATED WITH SHORT-COURSE AND LOW-DOSE CORTICOSTEROID THERAPY

OSTEONECROSIS OF THE JAW ASSOCIATED WITH SHORT-COURSE AND LOW-DOSE CORTICOSTEROID THERAPY

Blog Article

Medication related osteonecrosis of the jaw is a heterogeneous clinical entity with common pathology features and their diagnosis and management remains a dilemma for many clinicians.During the current SARS-CoV-2 virus pandemic, an extensive therapeutic arsenal is being used that includes traditional immunosuppressive and repurposed drugs, so it MEDI C W/MAG BERRY is important to understand their possible adverse effects.We describe the diagnosis, clinical course, and management of a 65-year-old female patient undergoing previously intravenous bisphosphonates (BPs) therapy and recently was treated with corticosteroid for the prevention of multi-inflammatory syndrome during the course of COVID-19.In this context, possible pathophysiological links between osteonecrosis of the jaw and medication used to treat non-severe COVID-19 infection are discussed.It should be underlined that osteonecrosis of the jaw unrelated to BPs may be a rare complication associated with concomitant corticotherapy.

This case highlights the need for rapid dissemination of clinical information related to the multidisciplinary care of patients with COVID-19 who Coconut Supplements were managed by corticosteroids.